Premium
Advanced glycation end products serve as ligands for lectin‐like oxidized low‐density lipoprotein receptor‐1(LOX‐1): biochemical and binding characterizations assay
Author(s) -
Chen Xiuping,
Zhang Tiantai,
Du Guanhua
Publication year - 2008
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.1502
Subject(s) - glycation , scavenger receptor , cd36 , biochemistry , chemistry , receptor , chinese hamster ovary cell , low density lipoprotein , ribose , lipoprotein , fructosamine , cholesterol , biology , diabetes mellitus , endocrinology , enzyme
Advanced glycation end products (AGEs) are a class of complex heterogeneous compounds which accumulate with age and is known to be involved in the pathogenesis of several diseases from diabetes to atherosclerosis. AGEs serve as ligands for multiple receptors including scavenger receptor (SR‐A), CD36, and SR‐BI. Lectin‐like oxidized low‐density lipoprotein receptor‐1 (LOX‐1) plays an important role in both atherosclerosis and is found to be an endothelial cell receptor for AGEs. To explore the binding characterization of AGEs to LOX‐1, AGEs were prepared by three different reducing sugars ( d ‐glucose, d ‐fructose, and d ‐ribose) and the biochemical characterization including, free amino groups, free amine content, fructosamine residues, carbonyl content, fluorescence, and absorbance were determined. The binding activity was determined by FITC labeled AGEs using Chinese hamster ovary‐K1 cells stably transfected with human LOX‐1 gene. The obtained AGEs showed significant differences in the extent of side chain modifications, carbonyl content, fluorescence, and absorption models. All of the AGEs showed specific and saturable binding to hLOX‐1‐CHO‐K1 cells. Furthermore, dose‐dependent binding processes were observed. However, the maximal cellular binding of AGEs differs between the sugars (glucose > ribose > fructose). In addition, oxidized low‐density lipoprotein (ox‐LDL) could significantly inhibit the binding of AGEs to LOX‐1 with different inhibitory efficiency. LOX‐1 serves as receptor for AGEs which may give some insight into the role of LOX‐1 in the pathogenesis of diabetes and related disorders. Copyright © 2008 John Wiley & Sons, Ltd.